AU2002212201A1 - Maurotoxin, pi1 and hstx1 derivatives - Google Patents

Maurotoxin, pi1 and hstx1 derivatives

Info

Publication number
AU2002212201A1
AU2002212201A1 AU2002212201A AU1220102A AU2002212201A1 AU 2002212201 A1 AU2002212201 A1 AU 2002212201A1 AU 2002212201 A AU2002212201 A AU 2002212201A AU 1220102 A AU1220102 A AU 1220102A AU 2002212201 A1 AU2002212201 A1 AU 2002212201A1
Authority
AU
Australia
Prior art keywords
derivatives
residue
maurotoxin
replaced
disulfide bridge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212201A
Inventor
Kamel Mabrouk
Herve Rochat
Jean-Marc Sabatier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellpep SA
Original Assignee
Cellpep SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0021639A external-priority patent/GB0021639D0/en
Priority claimed from GB0024538A external-priority patent/GB0024538D0/en
Application filed by Cellpep SA filed Critical Cellpep SA
Publication of AU2002212201A1 publication Critical patent/AU2002212201A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Derivatives of Maurotoxin (MTX) in which the native disulfide bridge pattern (Cys3-Cys24, Cys9-Cys29, Cys19, Cys31-Cys34) has been disrupted are useful for the treatment of pathologies associated with dysfunctioning and/or activation of Ca2+-activated and/or voltage-gated K+ channel subtypes, such as IKCa1 or Kv1.2. In one group of derivatives, one or two of the amino acid residues of maurotoxin have been replaced by different amino acid residues resulting in the disulfide bridge pattern being changed to Cys3-Cys24, Cys9-Cys29, Cys13-Cys31, Cys19-Cys34. Exemplary substitutions include the Arg residue at position 14 and/or the Lys residue at position 15 replaced by a Gln residue and the Gly residue at position 33 replaced by an Ala residue. Pi1 and HsTx1 derivatives with disrupted native disulfide bridge patterns are similarly useful.
AU2002212201A 2000-09-04 2001-09-03 Maurotoxin, pi1 and hstx1 derivatives Abandoned AU2002212201A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0021639.0 2000-09-04
GB0021639A GB0021639D0 (en) 2000-09-04 2000-09-04 Maurotoxin derivatives
GB0024538A GB0024538D0 (en) 2000-10-06 2000-10-06 Maurotoxin pil and hstx1 derivatives
GB0024538.1 2000-10-06
PCT/EP2001/010173 WO2002020596A2 (en) 2000-09-04 2001-09-03 Maurotoxin, pi1 and hstx1 derivatives

Publications (1)

Publication Number Publication Date
AU2002212201A1 true AU2002212201A1 (en) 2002-03-22

Family

ID=26244958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212201A Abandoned AU2002212201A1 (en) 2000-09-04 2001-09-03 Maurotoxin, pi1 and hstx1 derivatives

Country Status (7)

Country Link
US (2) US20040039167A1 (en)
EP (1) EP1315747B1 (en)
AT (1) ATE321778T1 (en)
AU (1) AU2002212201A1 (en)
DE (1) DE60118418T2 (en)
ES (1) ES2261491T3 (en)
WO (1) WO2002020596A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
EP2162540A2 (en) * 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
DE202013104200U1 (en) 2013-09-13 2013-10-10 Flühs Drehtechnik GmbH Single lever cartridge
WO2015061826A1 (en) 2013-10-28 2015-05-07 Monash University Novel scorpion toxin analogue and method for treating autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100278378B1 (en) * 1991-10-12 2001-01-15 린다 에스. 스티븐슨 Thiol redox protein used to reduce disulfide bonds
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
CA2253937A1 (en) * 1996-05-10 1997-11-20 Phylomed Corporation Methods for oxidizing disulfide bonds using ozone
GB9627115D0 (en) * 1996-12-31 1997-02-19 Centre Nat Rech Scient Alpha-amino-butyrate derivatives of venoms

Also Published As

Publication number Publication date
US20040039167A1 (en) 2004-02-26
US7829666B2 (en) 2010-11-09
EP1315747A2 (en) 2003-06-04
WO2002020596A2 (en) 2002-03-14
ATE321778T1 (en) 2006-04-15
WO2002020596A3 (en) 2002-08-01
ES2261491T3 (en) 2006-11-16
DE60118418D1 (en) 2006-05-18
DE60118418T2 (en) 2007-01-11
US20090062198A1 (en) 2009-03-05
EP1315747B1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
DK1877435T3 (en) Glucagon-like peptide 2 (GLP-2) analogs
MX2009004701A (en) Selective glucagon-like-peptide-2 (glp-2) analogues.
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
CY1113850T1 (en) NEW INSULIN PRODUCERS
DK1941867T3 (en) Polypeptide with Modified Kunitz Domain
ATE417595T1 (en) KERATIN-BINDING POLYPEPTIDES
NZ506447A (en) Peptide analogues of insulin with alanine substitutions and pharmaceutical use
MXPA04003333A (en) Remodeling and glycoconjugation of peptides.
PE20130615A1 (en) POLYPEPTIDES OF THE VARIANT ACTIVIN RECEPTOR AND USE OF THEM
MXPA05003730A (en) Erythropoietin: remodeling and glycoconjugation of erythropoietin.
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
AU2002212201A1 (en) Maurotoxin, pi1 and hstx1 derivatives
KR980002066A (en) Mutant human growth hormone and uses thereof
GB1601754A (en) Pharmacologically active aligopeptide derivatives
DK0918795T3 (en) Antiangiogenic drugs for the treatment of cancer, arthritis and retinopathy
BRPI0411820A (en) pharmaceutical composition
GEP20084464B (en) Mutated neublastin
EP1586583A3 (en) Compounds that block C5a complement receptor and their use in therapy
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
ECSP003457A (en) PROTEIN C DERIVATIVES
CY1111301T1 (en) POLYPeptides Derived from the Amyloid Peptide Precursor (ARP) PREMIUM AND THEIR USES
ATE492637T1 (en) PEPTIDES BINDING TO THE LCK-SH3 AND HCK-SH3 DOMAIN
SE0001988D0 (en) Novel polypeptides and use thereof